ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Michael Scally MD

Doctor of Medicine
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Acadia Pharmaceuticals
ACADIA Pharmaceuticals Inc.: NASDAQ:ACAD quotes & news - Google Finance


ACADIA Announces Pimavanserin Meets Primary and Key Secondary Endpoints in Pivotal Phase III Parkinson’s Disease Psychosis Trial
Pimavanserin Demonstrates Highly Significant Antipsychotic Efficacy and Maintenance of Motor Control in Parkinson’s Patients
Significant Improvements Also Observed in All Secondary and Exploratory Measures
Acadia Pharmaceuticals - Investor Relations -News Release


ACADIA Pharmaceuticals Conference Call to Present Top-line Results from its Pivotal Phase III Pimavanserin Parkinson's Disease Psychosis Trial
Acadia Pharmaceuticals - Investor Relations -Event Details


Acadia’s Value Heavily Dependent On Pimavanserin Data
Acadia's Value Heavily Dependent On Pimavanserin Data

In the past we’ve written extensively on the redesigns management has instituted in the -020 trial versus the failed -012 and -014 studies. Our article from January 2012, “Will Third Time Be A Charm For Acadia Pharmaceuticals?” provides a good analysis of these changes.


ACADIA Pharmaceuticals Announces $86 Million Equity Financing
--Proceeds to Support Completion of Pimavanserin Phase III Program--
Acadia Pharmaceuticals - Investor Relations -News Release
 
Top